2011’s biggest patent expiries

INICIO/Políticas y legislación | Posted 22/04/2011 post-comment0 Post your comment

2011 looks set to be a bumper year for generics, with patents from some of the biggest selling drugs set to expire.

picture 85

Just looking at the top five selling drugs, US sales of more than US$10 billion will be open to competition by the generics industry.

Key patent expiries, according to data from EvaluatePharma, include Lipitor (atorvastatin – Pfizer), Zyprexa (olanzapine – Eli Lilly), Levaquin (levofloxacin – Johnson & Johnson), Concerta (methylphenidate – Johnson & Johnson) and Protonix (pantoprazole – Pfizer). These patent expiries, while being very good news for the generics industry and patients could deal a major blow to some of the largest pharmaceutical companies.

In 2010, with US$10.8 billion in worldwide sales, Lipitor accounted for 15.8% of Pfizer’s total revenue. While in 2010, Zyprexa’s worldwide revenues were just over US$5 billion, or nearly 22% of Eli Lilly’s full year sales.

Once drugs lose patent protection, lower-price generics rapidly gain market share, often siphoning off as much as 90% of sales. Benefits to patients are substantial, with generics averaging about 30% of the price of the brand-name originals.

Related article

2012’s biggest patent expiries

Source: EvaluatePharma

comment icon Comments (0)
Post your comment
Related content
Consulta pública para la modificación de la regulación de biosimilares
02 AA010638
INICIO/Políticas y legislación Posted 16/01/2024
COFEPRIS promueve la cooperación regulatoria en América
Latin America 1638px
INICIO/Políticas y legislación Posted 12/12/2023
Pendiente la decisión de ANVISA sobre las ‘skinny labels’ para genéricos
Labelling V14I26
INICIO/Políticas y legislación Posted 14/11/2023
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010